Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use-Reference-Cited by-同舟云学术

Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use

Published:2007-04-01 Issue:4 Volume:12 Page:484-494
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Ozer Howard¹,Mirtsching Barry²,Rader Michael³,Luedke Susan⁴,Noga Stephen J.⁵,Ding Beiying⁶,Dreiling Lyndah⁶

Affiliation:

1. a Section of Hematology/Oncology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma,USA

2. b Center for Oncology Research and Treatment, PA, Dallas, Texas, USA

3. c Union State Bank Cancer Center, Nyack Hospital, Nyack, New York, USA

4. d St. Louis Cancer & Breast Institute, St. Louis, Missouri, USA

5. e Alvin & Lois Lapidus Cancer Institute, Baltimore, Maryland, USA

6. f Amgen Inc., Thousand Oaks, California, USA

Abstract

Learning Objectives After completing this course, the reader will be able to: Describe the incidence of neutropenia-related endpoints when pegfilgrastim was administered in the first and subsequent chemotherapy cycles.Compare results with data reflecting current practice standards.Discuss the relevance of pegfilgrastim use beginning in the first cycle of chemotherapy. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

Funder

Amgen Inc.

Thousand Oaks, CA

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.12-4-484

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases receiving cytotoxic therapy: results of LEGERITY, a multicenter retrospective-and-prospective observational post-marketing study;Journal of Modern Oncology;2024-02-21

2. Pegfilgrastim on febrile neutropenia in pediatric and adolescent cancer patients: a systematic review and meta-analysis;Hematology;2023-01-31

3. Evaluating the safety and effectiveness of PegaGen® (pegfilgrastim) for the prevention of chemotherapy-induced febrile neutropenia: a post-marketing surveillance study;Supportive Care in Cancer;2022-07-06

4. Efficacy and Safety for the Use of Half-Dosed Pegylated Granulocyte Colony-Stimulating Factors in Preventing Febrile Neutropenia During Chemotherapy in Patients With Malignant Tumors: A Multicenter, Open-Labeled, Single-Arm Phase 2 Trial;FRONT ONCOL;2022

5. Efficacy and Safety for the Use of Half-Dosed Pegylated Granulocyte Colony-Stimulating Factors in Preventing Febrile Neutropenia During Chemotherapy in Patients With Malignant Tumors: A Multicenter, Open-Labeled, Single-Arm Phase 2 Trial;Frontiers in Oncology;2022-04-27